Summary

The valuation of the at-home blood collection devices market in 2024 is USD 93 million and this market is projected to reach USD 135 million by 2029, growing at a CAGR of 7.6% for the period from 2024 to 2029. High demand for at-home blood collection & microsampling devices is primarily on account of rising infectious diseases, chronic disorders, and lifestyle-related diseases.
Pathogenic microorganisms, a continuous danger to public health, have been a major threat and reason for many deathly infectious diseases causing outbreaks all over the world. Periodic monitoring of the viral load, antibodies, and other biomarkers is necessary in infectious diseases like HIV/AIDS, hepatitis, and new viral outbreaks to trace the progression of disease and effectiveness of treatment.
At-home blood collection devices are functional because they allow patients to collect blood samples within their environment, which reduces exposure in healthcare settings and allows for timely testing. The ease of use, privacy, and convenience are what drives this trend with the at-home blood collection device. Hence, due to increased infectious diseases cases, it should boost the growth and adoption of at-home blood collection kits.
“Fingerstick method segment has taken the larger portion of the at-home blood collection devices market, by collection method, during the forecast period.”
The at-home blood collection devices market can be segmented, based on the collection method, into fingerstick, push-button, and other sample collection methods. In 2023, the fingerstick method held the major share of the at-home blood collection devices market. Moreover, broad acceptance of fingerstick has been attributed to compliance with regulatory standards that ascertains additional safety and reliability for its use at home. This further consolidates its leading position on the market, as it can easily find its place within daily routine and allow regular health monitoring without professional interventions.
“Liquid samples segment accounted for the highest growth rate in the at-home blood collection devices market, by sample type, during the forecast period.”
The at-home blood collection devices market is further divided into liquid and dried samples based on the type of sample. Liquid blood samples are expected to grow at a higher CAGR in the at-home blood collection devices market as compared to dried samples, due to their superior performance for delivering accurate and immediate diagnostic results. Compared to a dried sample that is to be rehydrated and its problems of stability and degradation, liquid blood samples are way more reliable for the same purpose. Another reason blood in its liquid form is becoming more favored is that it is easier to collect enough volume to perform a wide variety of tests, and technological advances make this process easy to conduct and relatively painless. It is foreseen that liquid blood samples will continue to see rapid market growth due to their support for advanced testing methodologies and an increasing demand for real-time health monitoring.
“Asia Pacific: The fastest-growing region in at-home blood collection devices market.”
The worldwide market for at-home blood collection devices is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. The Asia Pacific region is poised to experience the most notable CAGR within the at-home blood collection devices market. Increasing collaborations between academic institutions, research organizations, and healthcare companies in the Asia Pacific region contribute to the advancement and commercialization of at-home blood collection devices technologies.
Rapid urbanization and growing disposable incomes have resulted in increased investments in healthcare and growing consumer demand for convenient health monitoring solutions.
The break-up of the profile of primary participants in the at-home blood collection devices market:
• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%
The key players in this market are Trajan Group Holdings Limited (Australia), Tasso, Inc. (US), YourBio Health, Inc. (US), A. Menarini Diagnostics (UK), R-Biopharm AG (Germany), Sussex Pathology Limited (UK), ImmunoServ (UK), Labonovum (Netherlands), Alpha Laboratories (UK), Lipomic Healthcare (India), Tri-Tech Forensics (US), RDA Spot Inc (Lithuania), Spot On Sciences (US), Capitainer (Sweden), PanoHealth (US), Lameditech (South Korea), Sara Healthcare (India), Owen Mumford Ltd (UK), RedDrop Dx, Inc. (US), AdvaCare Pharma (US), Naulakha Industries (India), and Phoenix Healthcare Solutions, LLC (US).
Research Coverage:
This research report categorizes the at-home blood collection devices market by product (Fingerstick Blood Collection Kits, DBS Collection Kits, Lancets, Other Products), by collection methods (Fingerstick Method, Push-button Method, Other Methods), by usability (Single-use Blood Collection Devices and Reusable Blood Collection Devices), by sample type (Dried Blood Samples and Liquid Blood Samples), by device type (Self-collection Devices and Professional Collection Devices), by application (Disease Diagnostics, Health Screening & Preventive Health, Clinical Trials & Research, Other Applications), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the at-home blood collection devices market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the at-home blood collection devices market. Competitive analysis of upcoming startups in the at-home blood collection devices market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall at-home blood collection devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing burden of chronic disorders and lifestyle-related health conditions, Increasing prevalence of infectious diseases, Rising geriatric population and incidence of age-associated diseases, and Rising demand for painless devices and growing technological advancements), opportunities (Growth opportunities in emerging economies), restraints (Unregulated use of products for at-home blood collection and Pricing pressure owing to reimbursement cuts and budget constraints), and challenges (Inadequate access to microsampling devices in resource-limited areas) influencing the growth of the at-home blood collection devices market market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the at-home blood collection devices market market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the at-home blood collection devices market market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the at-home blood collection devices market market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Tasso, Inc. (US), Trajan Group Holdings Limited (Australia), YourBio Health, Inc. (US), Capitainer (Sweden), and A. Menarini Diagnostics s.r.l (UK).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 27
1.3 STUDY SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 YEARS CONSIDERED 29
1.3.3 CURRENCY CONSIDERED 29
1.4 STAKEHOLDERS 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.2 RESEARCH APPROACH 30
2.2.1 SECONDARY DATA 31
2.2.1.1 Key data from secondary sources 32
2.2.2 PRIMARY DATA 33
2.2.2.1 Primary sources 33
2.2.2.2 Key data from primary sources 34
2.2.2.3 Key industry insights 35
2.2.2.4 Breakdown of primary interviews 35
2.3 MARKET SIZE ESTIMATION 36
2.3.1 BOTTOM-UP APPROACH 36
2.3.1.1 Approach 1: Company revenue estimation approach 37
2.3.1.2 Approach 2: Presentations of companies and primary interviews 37
2.3.1.3 Growth forecast 37
2.3.1.4 CAGR projections 38
2.3.2 TOP-DOWN APPROACH 38
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 39
2.5 MARKET SHARE 41
2.6 STUDY ASSUMPTIONS 41
2.7 GROWTH RATE ASSUMPTIONS 41
2.8 RISK ASSESSMENT 42
2.8.1 RISK ASSESSMENT: AT-HOME BLOOD COLLECTION DEVICES MARKET 42
2.9 LIMITATIONS 42
3 EXECUTIVE SUMMARY 43
 
4 PREMIUM INSIGHTS 50
4.1 AT-HOME BLOOD COLLECTION DEVICES MARKET OVERVIEW 50
4.2 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY PRODUCT, 2024 VS. 2029 51
4.3 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY SAMPLE TYPE, 2024 VS. 2029 51
4.4 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY COLLECTION METHOD,
2024 VS. 2029 52
4.5 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY DEVICE TYPE, 2024 VS. 2029 52
4.6 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY USABILITY, 2024 VS. 2029 53
4.7 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY APPLICATION, 2024 VS. 2029 53
4.8 AT-HOME BLOOD COLLECTION DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 56
5.2.1.1 Increasing burden of chronic disorders and lifestyle-related health conditions 56
5.2.1.2 Increasing prevalence of infectious diseases 57
5.2.1.3 Rising geriatric population and incidence of age-associated diseases 58
5.2.1.4 Rising demand for painless devices and growing technological advancements 59
5.2.2 RESTRAINTS 60
5.2.2.1 Unregulated use of products for at-home blood collection 60
5.2.2.2 Pricing pressure owing to reimbursement cuts and budget constraints 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 Growth opportunities in emerging economies 61
5.2.4 CHALLENGES 61
5.2.4.1 Inadequate access to microsampling devices in resource-limited areas 61
5.3 PRICING ANALYSIS 62
5.4 PATENT ANALYSIS 64
5.4.1 LIST OF MAJOR PATENTS 65
5.5 VALUE CHAIN ANALYSIS 66
5.6 SUPPLY CHAIN ANALYSIS 67
5.7 TRADE ANALYSIS 68
5.7.1 TRADE ANALYSIS FOR LANCETS, CANNULAS, AND CATHETERS 68
5.8 ECOSYSTEM ANALYSIS 69
5.8.1 AT-HOME BLOOD COLLECTION DEVICES MARKET: ROLE IN ECOSYSTEM 70
5.9 PORTER’S FIVE FORCES ANALYSIS 71
5.9.1 THREAT OF NEW ENTRANTS 72
5.9.2 THREAT OF SUBSTITUTES 72
5.9.3 BARGAINING POWER OF BUYERS 72
5.9.4 BARGAINING POWER OF SUPPLIERS 72
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 73
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 73
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 73
5.10.2 BUYING CRITERIA 74
5.11 REGULATORY LANDSCAPE 74
5.11.1 NORTH AMERICA 75
5.11.1.1 US 75
5.11.1.2 Canada 75
5.11.2 EUROPE 75
5.11.3 ASIA PACIFIC 76
5.11.3.1 China 76
5.11.3.2 Japan 76
5.11.3.3 India 77
5.11.4 LATIN AMERICA 77
5.11.4.1 Brazil 77
5.11.4.2 Mexico 78
5.11.5 MIDDLE EAST 78
5.11.5.1 Africa 78
5.11.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
5.12 TECHNOLOGY ANALYSIS 80
5.12.1 KEY TECHNOLOGIES 81
5.12.1.1 Lancets 81
5.12.2 COMPLEMENTARY TECHNOLOGIES 81
5.12.2.1 Dried Blood Spot Collection 81
5.12.3 ADJACENT TECHNOLOGIES 82
5.12.3.1 Laser Lancets 82
5.13 KEY CONFERENCES AND EVENTS IN 2024–2025 82
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
5.15 INVESTMENT & FUNDING SCENARIO 84
5.16 CASE STUDY ANALYSIS 84
5.16.1 ASSESSING DIAGNOSTIC ACCURACY OF VOLUMETRIC ABSORPTIVE MICROSAMPLING COMPARED TO GOLD STANDARD METHOD 84
5.17 IMPACT OF AI ON AT-HOME BLOOD COLLECTION DEVICES MARKET 85
6 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY PRODUCT 86
6.1 INTRODUCTION 87
6.2 LANCETS 87
6.2.1 HIGH AFFORDABILITY AND FREQUENT USE TO DRIVE UPTAKE OF LANCETS 87
6.3 DRIED BLOOD SPOT COLLECTION KITS 90
6.3.1 SUPPORT FOR SHORT-TERM STORAGE TO DRIVE MARKET 90
6.4 FINGERSTICK BLOOD COLLECTION KITS 93
6.4.1 DEMAND FOR PAINLESS TECHNOLOGIES TO HAMPER MARKET GROWTH 93
6.5 OTHER PRODUCTS 96
7 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY SAMPLE TYPE 100
7.1 INTRODUCTION 101
7.1.1 PRIMARY NOTES 101
7.2 LIQUID BLOOD SAMPLES 102
7.2.1 FAVORABLE REGULATORY AND INVESTMENT LANDSCAPES TO DRIVE ADOPTION 102
7.3 DRIED BLOOD SAMPLES 105
7.3.1 EASY COLLECTION AND REDUCED REQUIREMENT FOR COLD STORAGE TO SUPPORT UPTAKE OF DRIED BLOOD-BASED DEVICES 105
8 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY COLLECTION METHOD 110
8.1 INTRODUCTION 111
8.2 FINGERSTICK SAMPLE COLLECTION 111
8.2.1 HIGH AFFORDABILITY AND ACCESSIBILITY TO DRIVE MARKET 111
8.3 PUSH-BUTTON SAMPLE COLLECTION 114
8.3.1 CONSISTENCY AND RELIABILITY TO SUPPORT HOME-USE ADOPTION 114
8.4 OTHER SAMPLE COLLECTION METHODS 117
9 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY DEVICE TYPE 121
9.1 INTRODUCTION 122
9.2 SELF-COLLECTION DEVICES 122
9.2.1 INCREASED PRIVACY AND CONFIDENTIALITY OF SELF-COLLECTION DEVICES TO DRIVE MARKET 122
9.3 PROFESSIONAL COLLECTION DEVICES 125
9.3.1 GROWING AWARENESS AND USAGE OF SELF-COLLECTION DEVICES TO HINDER ADOPTION 125
10 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY USABILITY 129
10.1 INTRODUCTION 130
10.2 SINGLE-USE BLOOD COLLECTION DEVICES 130
10.2.1 INCREASED AFFORDABILITY OF SINGLE-USE DEVICES TO DRIVE ADOPTION 130
10.3 REUSABLE BLOOD COLLECTION DEVICES 133
10.3.1 NEED FOR PAINLESS TECHNOLOGIES TO PROPEL UPTAKE 133
11 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY APPLICATION 137
11.1 INTRODUCTION 138
11.2 HEALTH SCREENING & PREVENTIVE HEALTH 138
11.2.1 GROWING AWARENESS ON REGULAR HEALTH ASSESSMENTS TO FUEL MARKET GROWTH 138
11.3 DISEASE DIAGNOSTICS 141
11.3.1 INCREASING DEMAND FOR EARLY DISEASE DETECTION TO DRIVE MARKET 141
11.4 CLINICAL TRIALS & RESEARCH 144
11.4.1 NEED FOR COMPREHENSIVE & STANDARDIZED RESEARCH FINDINGS TO PROPEL MARKET GROWTH 144
11.5 OTHER APPLICATIONS 147
12 AT-HOME BLOOD COLLECTION DEVICES MARKET, BY REGION 151
12.1 INTRODUCTION 152
12.2 NORTH AMERICA 152
12.2.1 US 156
12.2.1.1 Advanced infrastructure and high healthcare expenditure to drive market 156
12.2.2 CANADA 159
12.2.2.1 Rising prevalence of kidney diseases to propel demand 159
12.3 EUROPE 162
12.3.1 GERMANY 165
12.3.1.1 Increasing healthcare expenditure to propel market 165
12.3.2 UK 168
12.3.2.1 Increasing prevalence of lifestyle diseases to drive market 168
12.3.3 FRANCE 171
12.3.3.1 Rising R&D expenditure to provide growth opportunities 171
12.3.4 ITALY 173
12.3.4.1 Growing diabetes prevalence to sustain demand for testing 173
12.3.5 SPAIN 176
12.3.5.1 Growth in elderly demographics in Spain to propel market 176
12.3.6 REST OF EUROPE 179
12.4 ASIA PACIFIC 181
12.4.1 CHINA 185
12.4.1.1 China to hold largest share of APAC market 185
12.4.2 JAPAN 188
12.4.2.1 Well-established healthcare system to support market 188
12.4.3 INDIA 191
12.4.3.1 Large patient population and rising prevalence of chronic diseases to drive market 191
12.4.4 REST OF ASIA PACIFIC 194
12.5 LATIN AMERICA 197
12.5.1 BRAZIL 200
12.5.1.1 Brazil to dominate LATAM market 200
12.5.2 MEXICO 203
12.5.2.1 Rising prevalence of chronic diseases to drive market 203
12.5.3 REST OF LATIN AMERICA 206
 
12.6 MIDDLE EAST & AFRICA 208
12.6.1 INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET 208
12.7 GCC COUNTRIES 211
12.7.1 INFRASTRUCTURAL DEVELOPMENT AND GROWING DISEASE INCIDENCE TO DRIVE MARKET 211
13 COMPETITIVE LANDSCAPE 215
13.1 INTRODUCTION 215
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 215
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AT-HOME BLOOD COLLECTION DEVICES MARKET 215
13.3 REVENUE SHARE ANALYSIS 217
13.4 MARKET SHARE ANALYSIS 217
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 219
13.5.1 STARS 219
13.5.2 EMERGING LEADERS 219
13.5.3 PERVASIVE PLAYERS 219
13.5.4 PARTICIPANTS 219
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 221
13.5.5.1 Company footprint 221
13.5.5.2 Product footprint 222
13.5.5.3 Regional footprint 223
13.5.5.4 Application footprint 224
13.5.5.5 Sample type footprint 225
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 225
13.6.1 PROGRESSIVE COMPANIES 225
13.6.2 RESPONSIVE COMPANIES 225
13.6.3 DYNAMIC COMPANIES 226
13.6.4 STARTING BLOCKS 226
13.6.5 COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, 2023 227
13.7 VALUATION & FINANCIAL METRICS 227
13.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 228
13.8.1 SARA HEALTHCARE 229
13.8.2 OWEN MUMFORD 229
13.8.3 A. MENARINI DIAGNOSTICS S.R.L 229
13.9 COMPETITIVE SCENARIO 229
13.9.1 PRODUCT LAUNCHES 229
13.9.2 DEALS 230
13.9.3 EXPANSIONS 231
13.9.4 OTHER DEVELOPMENTS 232
 
14 COMPANY PROFILES 233
14.1 KEY PLAYERS 233
14.1.1 TASSO, INC. 233
14.1.1.1 Business overview 233
14.1.1.2 Products offered 233
14.1.1.3 Recent developments 234
14.1.1.3.1 Product approvals 234
14.1.1.3.2 Deals 234
14.1.1.4 MnM view 236
14.1.1.4.1 Right to win 236
14.1.1.4.2 Strategic choices 236
14.1.1.4.3 Weaknesses & competitive threats 236
14.1.2 TRAJAN GROUP HOLDINGS LIMITED 237
14.1.2.1 Business overview 237
14.1.2.2 Products offered 238
14.1.2.3 Recent developments 239
14.1.2.3.1 Deals 239
14.1.2.3.2 Other developments 240
14.1.2.4 MnM view 240
14.1.2.4.1 Right to win 240
14.1.2.4.2 Strategic choices 240
14.1.2.4.3 Weaknesses & competitive threats 240
14.1.3 YOURBIO HEALTH, INC. 241
14.1.3.1 Business overview 241
14.1.3.2 Products offered 241
14.1.3.3 Recent developments 242
14.1.3.3.1 Product approvals 242
14.1.3.4 MnM view 242
14.1.3.4.1 Right to win 242
14.1.3.4.2 Strategic choices 242
14.1.3.4.3 Weaknesses & competitive threats 242
14.1.4 CAPITAINER 243
14.1.4.1 Business overview 243
14.1.4.2 Products offered 243
14.1.4.3 Recent developments 244
14.1.4.3.1 Product launches 244
14.1.4.3.2 Deals 244
14.1.4.3.3 Other developments 245
14.1.5 A. MENARINI DIAGNOSTICS S.R.L (MENARINI GROUP) 246
14.1.5.1 Business overview 246
14.1.6 R-BIOPHARM AG 247
14.1.6.1 Business overview 247
14.1.6.2 Products offered 247
14.1.7 SUSSEX PATHOLOGY LIMITED 248
14.1.7.1 Business overview 248
14.1.7.2 Products offered 248
14.1.7.3 Recent developments 248
14.1.7.3.1 Deals 248
14.1.8 IMMUNOSERV 249
14.1.8.1 Business overview 249
14.1.8.2 Products offered 249
14.1.9 LABONOVUM 250
14.1.9.1 Business overview 250
14.1.9.2 Products offered 250
14.1.10 ALPHA LABORATORIES 251
14.1.10.1 Business overview 251
14.1.10.2 Products offered 251
14.1.11 LIPOMIC HEALTHCARE 252
14.1.11.1 Business overview 252
14.1.11.2 Products offered 252
14.1.12 TRI-TECH FORENSICS 253
14.1.12.1 Business overview 253
14.1.12.2 Products offered 253
14.2 OTHER PLAYERS 254
14.2.1 RDA SPOT INC. 254
14.2.2 SPOT ON SCIENCES 254
14.2.3 PANOHEALTH 255
14.2.4 LAMEDITECH 255
14.2.5 SARA HEALTHCARE 256
14.2.6 OWEN MUMFORD LTD 256
14.2.7 REDDROP DX, INC. 257
14.2.8 ADVACARE PHARMA 257
14.2.9 NAULAKHA INDUSTRIES 258
14.2.10 PHOENIX HEALTHCARE SOLUTIONS, LLC 259
15 APPENDIX 260
15.1 DISCUSSION GUIDE 260
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 265
15.3 CUSTOMIZATION OPTIONS 267
15.4 RELATED REPORTS 267
15.5 AUTHOR DETAILS 268